COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Tara Hiltke, Ph.D.

Associate Director

Tara Hiltke

Dr. Hiltke assists in developing and implementing plans and goals for the Office of Cancer Clinical Proteomics Research. She also provides leadership and oversight to the Monoclonal Antibody Characterization program, and works in developing other methods of antigen generation. Previously, Dr. Hiltke served as a senior scientist/project manager in assay development at both Wellstat Diagnostics and BioVeris Corporation, where she developed clinical assays for diagnostic markers using electrochemiluminescence platform and magnetic beads. Dr. Hiltke holds a Ph.D. degree (1999) in biology from the University of Buffalo.